Subscribe
November 16, 2023 - CanSino Biologics Inc. (“CanSinoBIO” or “the Company”) (SSE: 688185, HKEX: 06185) is pleased to announce that it will be included in the MSCI China All Share Small Cap Index with effect from November 30, 2023 after the close of the market.
This reflects the recognition of the company’s business performance and development potential by the international index provider MSCI, and will benefit CanSinoBIO to expand investor base, increase stock liquidity, improve capital market influence to access a sustainable business development.
MSCI is a world’s leading investment research firm that provides stock indexes, portfolio risk and performance analytics and governance tools to global investment community. The MSCI index, perhaps the most influential index system worldwide, is a measure of stock market performance and reflects the current market conditions and trends. The MSCI China Index is one of the indices under the MSCI system, and includes companies that have representative, good business operations and strong growth potential.
Previously, the Company was included in the MSCI China Small Cap Index and MSCI China A Onshore Index, further enhancing its influence and reputation in the capital market.
